Lung Cancer
News from the FDA/CDC
FDA approves chemo-free combo for lung cancer
Conference Coverage
Quitting smoking just 2 years before lung cancer diagnosis may improve survival
Conference Coverage
Video coaching may relieve anxiety and distress for long-distance cancer caregivers
Conference Coverage
MRD surveillance can detect relapse before imaging in early-stage NSCLC
Relapse occurred in 9 of 10 patients who were positive for minimal residual disease but had no evidence of relapse on imaging.
Conference Coverage
ASCO goes ahead online, as conference center is used as hospital
News from the FDA/CDC
FDA approves selpercatinib for lung and thyroid RET tumors
News from the FDA/CDC
NSCLC: FDA approves capmatinib and companion assay
Capmatinib is the first FDA-approved treatment for NSCLC with MET exon 14 skipping mutations.
Conference Coverage
Capmatinib shows impressive results in METex14-mutated NSCLC
Capmatinib produced durable responses, even in patients with brain metastases.
From the Journals
COVID-19 death rate was twice as high in cancer patients in NYC study
The overall case fatality rate was 28% for cancer patients with COVID-19 and 14% for noncancer COVID-19 patients.
Feature
Three months of COVID-19 may mean 80,000 missed cancer diagnoses
A backlog of 22 million canceled or postponed tests for five common cancers is expected by early June.
Feature
Cancer screening, monitoring down during pandemic
Use of some tests came to “a near standstill” in early April.